Literature DB >> 26163105

Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study.

N Tozun1, O Ozdogan2, Y Cakaloglu3, R Idilman4, Z Karasu5, U Akarca5, S Kaymakoglu6, O Ergonul7.   

Abstract

The present study was designed to determine the seroprevalence of hepatitis B and C virus (HBV, HCV) infections and risk factors in the Turkish general population. Participants were enrolled from urban and rural areas of the predetermined 23 EUROSTAT NUTS 2 region. A two-stage stratified sampling method was used to select participants from these regions (n = 5460; 50.9% females; mean (SD) age: 40.8 (14.7) years). Sociodemographics, clinical characteristics and risk factors were recorded at home visits. The seropositivity rates for hepatitis B surface antigen (HBsAg), anti-HCV, anti-HBs and anti-HBc total were 4.0%, 1.0%, 31.9% and 30.6%, respectively. Among HBsAg-positive cases, 94.5% were anti-HBe-positive, 70.2% were HBV-DNA-positive and 2.8% were anti-HDV total positive; 99.1% of HBV infections were of genotype D. Close contact with a hepatitis patient (OR 3.24; 95% CI 2.25-4.66; p < 0.001), living in the southeastern region (OR 2.74; 95% CI 1.7-4.45; p < 0.001), male gender (OR 1.77; 95% CI 1.28-2.46; p < 0.001), being married (OR 1.62; 95% CI 1.02-2.57; p 0.038), educational level less than high school (OR 1.53; 95% CI 1.04-2.26; p 0.03), orodental interventions (OR 1.54; 95% CI 1.01-2.35; p 0.047) and a history of non-disposable syringe use (OR 1.4; 95% CI 1.01-1.96; p 0.045) were significant determinants of HBsAg positivity. Age ≥50 years (OR 2; 95% CI 1.09-4.3; p 0.026) was the only significant predictor of anti-HCV positivity. In conclusion, our findings revealed an HBsAg positivity in 4% and anti-HCV positivity in 1% of the adult population and at least one-third of the population has been exposed to HBV infection in Turkey.
Copyright © 2015 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hepatitis B; Turkey; hepatitis C; risk factors; seroprevalence

Mesh:

Year:  2015        PMID: 26163105     DOI: 10.1016/j.cmi.2015.06.028

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  39 in total

1.  Evaluation of the results of MOTAKK hepatitis C virus RNA genotyping and hepatitis delta virus external quality assessment programs during 2015-2016.

Authors:  Ersin Karataylı; Ege Soydemir; Zeynep Büşra Aksoy; Mehtap Kızılpınar; Aylin Altay Koçak; Senem Ceren Karataylı; Esra Yurdcu; Umut Yıldırım; Haluk Güriz; Gülendam Bozdayı; Cihan Yurdaydın; Osman İlhan; Yasin Yıldırım; Motakk Hcv Genotype And Hdv Study Group; A Mithat Bozdayı
Journal:  Turk J Gastroenterol       Date:  2019-11       Impact factor: 1.852

Review 2.  Regional Epidemiology, Burden, and Management of Hepatitis B Virus in the Middle East.

Authors:  Murat Akyıldız; Emel Ahıskalı; Müjdat Zeybel; Cihan Yurdaydın
Journal:  Clin Liver Dis (Hoboken)       Date:  2020-01-29

3.  Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report.

Authors:  Bilgehan Aygen; Ahmet Muzaffer Demir; Mahmut Gümüş; Oğuz Karabay; Sabahattin Kaymakoğlu; Aydın Şeref Köksal; İftihar Köksal; Necati Örmeci; Fehmi Tabak
Journal:  Turk J Gastroenterol       Date:  2018-05       Impact factor: 1.852

4.  Real-life experience of ledipasvir and sofosbuvir single-tablet regimen among chronic hepatitis C patients in Turkey.

Authors:  Tansu Yamazhan; İlker Turan; Galip Ersöz; Fulya Günşar; Hüsnü Pullukçu; Nilay Danış; Nalan G Ünal; Rukiye Vardar; Nevin Oruç; Fatih Tekin; Meltem Taşbakan; Oğuz R Sipahi; Ulus S Akarca
Journal:  Turk J Gastroenterol       Date:  2020-03       Impact factor: 1.852

5.  Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience.

Authors:  Bülent Değertekin; Mehmet Demir; Ulus S Akarca; Haluk Tarık Kani; Enver Üçbilek; Emre Yıldırım; Fatih Güzelbulut; Ayhan Balkan; Sezgin Vatansever; Nilay Danış; Melek Demircan; Aliye Soylu; Serkan Yaras; Aysun Kartal; Ayşe Kefeli; Feyza Gündüz; Kendal Yalçın; Elife Erarslan; Murat Aladağ; Murat Harputluoğlu; Ayşegül Özakyol; Tuncer Temel; Mesut Akarsu; Hale Sümer; Mete Akın; Bülent Albayrak; İlker Sen; Hüseyin Alkım; Ahmet Uyanıkoğlu; Kader Irak; Sinem Öztaşkın; Çağrı Burak Uğurlu; Şevkican Güneş; Selim Gürel; Kenan Nuriyev; İsmail İnci; Sabite Kaçar; Dinç Dinçer; Levent Doğanay; Hüseyin Savaş Göktürk; Ali Mert; Arif Mansur Coşar; Hakan Dursun; Roni Atalay; Sabiye Akbulut; Yasemin Balkan; Hayrettin Koklu; Halis Şimşek; Osman Özdoğan; Mehmet Çoban
Journal:  Turk J Gastroenterol       Date:  2020-12       Impact factor: 1.852

6.  Changes on Hepatitis C virus genotype distribution in Western Turkey: Evaluation of twelve-year data.

Authors:  Alev Çetin Duran; Özgül Kaya Çetinkaya; Ayça Arzu Sayıner; Gülşah Şeydaoğlu; Emre Özkarataş; Hakan Abacıoğlu
Journal:  Turk J Gastroenterol       Date:  2020-02       Impact factor: 1.852

7.  Can family physicians have a role in eradication of hepatitis c infection?

Authors:  Ahmet Rıza Şahin; Ayşegül Erdoğan; Kadir Gisi; Murat İspiroğlu; Selma Ateş; Ramazan Azim Okyay; Selçuk Nazik; Bülent Kantarçeken
Journal:  Turk J Gastroenterol       Date:  2020-05       Impact factor: 1.852

8.  Rheumatologists' awareness of hepatitis B reactivation before immunosuppressive therapy.

Authors:  Bilal Toka; Ahmet Tarik Eminler; Emel Gönüllü; Mukaddes Tozlu; Mustafa Ihsan Uslan; Erkan Parlak; Oğuz Karabay; Aydin Seref Koksal
Journal:  Rheumatol Int       Date:  2019-09-13       Impact factor: 2.631

9.  HBsAg, Anti-HCV and Anti-HIV Seroprevalance Among Drug Users: a Retrospective Assessment.

Authors:  Imre Altuğlu; Selin Tanyeri; Ayşın Zeytinoğlu; Ayşe Ender Altintoprak
Journal:  Noro Psikiyatr Ars       Date:  2019-07-16       Impact factor: 1.339

10.  What Is the Risk of Reactivation in Patients with Resolved and Past HBV Infection During Immunosuppressive Therapy If HBV-DNA Negative before Treatment?

Authors:  Salih Tokmak; Yüksel Gümürdülü; Didem A Taş; İbrahim O Kara; Ahmet B Güzel
Journal:  Turk J Gastroenterol       Date:  2021-03       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.